ReNeuron is a UK-based stem cell research company whose shares were listed on the Alternative Investment Market, until it delisted in August 2024 after entering administration.[1] Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.

ReNeuron
Company typePublic company
LSERENE
IndustryStem cell research & development
Founded1997
HeadquartersSurrey, England, UK
Key people
chairman = Trevor Jones
Websitereneuron.com

As of 2010 ReNeuron was testing the effects of neural stem cells on spinal cords for neuroregeneration.[2] They were also testing the use of fetal stem cells on stroke patients.[3]

References

edit
  1. ^ Life sciences firm ReNeuron to delist as it aims to exit administration - MSN, 30 August 2024
  2. ^ Cookson, Clive (4 May 2010). "Regenerative medicine: Possibilities multiply for nerve cell regrowth". Retrieved 23 May 2010.
  3. ^ "EU agency prepares to assess first stem cell drug". Reuters. 12 May 2010. Retrieved 23 May 2010.
edit